Overview and Scope
Rare neurological disease treatment refers to the medical interventions and therapies aimed at managing symptoms, slowing disease progression, and improving the quality of life for individuals affected by rare neurological conditions. Rare neurological diseases refer to uncommon neurological disorders affecting the nervous system, including the brain, spinal cord, and peripheral nerves.
Sizing and Forecast
The rare neurological disease treatment market size has grown strongly in recent years. It will grow from $8.98 billion in 2023 to $9.79 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to biosimilars in rare disease treatment, globalization of clinical trials, healthcare reimbursement policies, orphan drug designations, advancements in genetic research.
The rare neurological disease treatment market size is expected to see strong growth in the next few years. It will grow to $13.41 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to improved diagnostic tools, precision medicine advancements, patient-centric drug development, integration of real-world evidence, telemedicine for patient support, shift towards personalized therapies. Major trends in the forecast period include technological innovations, ai in drug discovery, blockchain for data security, machine learning in drug discovery.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report
Segmentation & Regional Insights
The rare neurological disease treatment market covered in this report is segmented –
1) By Drug Type: Biologics, Small Molecules
2) By Therapy: Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Cyberknife, Other Therapies
3) By Mode Of Administration: Oral, Injectable, Other Modes Of Administration
4) By Disorders: Aicardi Syndrome, Aicardi-Goutières Syndrome, Reflex Sympathetic Dystrophy Syndrome, Battaglia-Neri Syndrome, Creutzfeldt Jakob Disease, Agnosia, Other Disorders
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Drug Store, Online Pharmacies
North America was the largest region in the rare neurological diseases treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare neurological disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=12146&type=smp
Major Driver Impacting Market Growth
The prevalence of rare neurological diseases is expected to propel the growth of the rare neurological disease treatment market going forward. Rare neurological diseases refer to low-prevalence neurological disorders, including Huntington’s disease, ALS (amyotrophic lateral sclerosis), Rett syndrome, and various forms of muscular dystrophy. Treating rare neurological diseases involves multiple approaches to manage symptoms, slow disease progression, and improve the quality of life for individuals affected by these conditions. For instance, in January 2023, according to an article published by BioMed Central Ltd., a UK-based publisher of open-access scientific journals, the collective prevalence of Rett syndrome was determined to be 7.1 per 100,000 females in a combined sample size of 9.57 million women, with a total of 673 confirmed cases. Therefore, the prevalence of rare neurological diseases is driving the growth of the rare neurological disease treatment market.
Key Industry Players
Major companies operating in the rare neurological disease treatment market report are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi-Aventis SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Medtronic PLC, Teva Pharmaceutical Industries Ltd., CSL Limited, Biogen Inc., UCB S.A., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Jazz Pharmaceuticals PLC, Mitsubishi Tanabe Pharma Corporation, Neurocrine Biosciences Inc., Kedrion Biopharma Inc., Merz Pharma GmbH & Co. KGaA, Harmony Biosciences Holdings Inc., Amicus Therapeutics Inc., Revance Therapeutics Inc., Aquestive Therapeutics Inc., US WorldMeds LLC (Solstice Neurosciences LLC), Stoke Therapeutics Inc., Retrotope Inc.
The rare neurological disease treatment market report table of contents includes:
1. Executive Summary
2. Rare Neurological Disease Treatment Market Characteristics
3. Rare Neurological Disease Treatment Market Trends And Strategies
4. Rare Neurological Disease Treatment Market – Macro Economic Scenario
5. Global Rare Neurological Disease Treatment Market Size and Growth
.
.
.
31. Rare Neurological Disease Treatment Market Other Major And Innovative Companies
32. Global Rare Neurological Disease Treatment Market Competitive Benchmarking
33. Global Rare Neurological Disease Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Rare Neurological Disease Treatment Market
35. Rare Neurological Disease Treatment Market Future Outlook and Potential Analysis
36.Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
